Table 3.
Patient group | Recommendation | ASH/ISH | AHA/ACC/CDC | ESH/ESC | NICE | France | Taiwan | CHEP | China |
---|---|---|---|---|---|---|---|---|---|
High normal BP, high risk | Health behaviour modifications and pharmacological treatment | ✓ | |||||||
Stage 1, low risk | Health behaviour modifications and monitoring before initiating pharmacological treatment | ✓ | ✓ | ✓ | ✓ | ||||
Health behaviour modifications and pharmacological treatment | ✓ | ✓ | ✓ | ||||||
Stage 1, high risk | Health behaviour modifications and pharmacological treatment | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Stage 2, low risk | Health behaviour modifications and monitoring before initiating pharmacological treatment | ✓ | |||||||
Health behaviour modifications and pharmacological treatment | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
Stage 2, high risk | Health behaviour modifications and pharmacological treatment | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Elderly, >80 years | Health behaviour modifications and pharmacological treatment | Not specified | Not specified | ✓ (SBP ≥160 mmHg only) | Not specified | ✓ | Not specified | ✓ (SBP ≥160 mmHg only) | Not specified |
AHA/ACC/CDC American Hypertension Association/American College of Cardiology/Centers for Disease Control and Prevention, ASH/ISH American Society of Hypertension/International Society of Hypertension, CHEP Canadian hypertension education program, ESH/ESC European Society of Hypertension/European Society of Cardiology, JNC 8 Eighth Joint National Committee, NICE National Institute for Clinical Excellence (UK), SBP systolic blood pressure
aNote that this subject is not discussed in JNC 8 guidelines